[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IT8648065A0 - Formulazione farmaceutica liofilizzata di attivatore del plasminogeno dei tessuti e procedimento di preparazione relativo - Google Patents

Formulazione farmaceutica liofilizzata di attivatore del plasminogeno dei tessuti e procedimento di preparazione relativo

Info

Publication number
IT8648065A0
IT8648065A0 IT8648065A IT4806586A IT8648065A0 IT 8648065 A0 IT8648065 A0 IT 8648065A0 IT 8648065 A IT8648065 A IT 8648065A IT 4806586 A IT4806586 A IT 4806586A IT 8648065 A0 IT8648065 A0 IT 8648065A0
Authority
IT
Italy
Prior art keywords
freeze
pharmaceutical formulation
plasminogen activator
tissue plasminogen
preparation procedure
Prior art date
Application number
IT8648065A
Other languages
English (en)
Other versions
IT1191926B (it
Inventor
Johnston Michael Denis
Berger Henry
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521705A external-priority patent/GB8521705D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IT8648065A0 publication Critical patent/IT8648065A0/it
Application granted granted Critical
Publication of IT1191926B publication Critical patent/IT1191926B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
IT48065/86A 1985-05-28 1986-05-27 Formulazione farmaceutica liofilizzata di attivatore del plasminogeno dei tessuti e procedimento di preparazione relativo IT1191926B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB858521705A GB8521705D0 (en) 1985-08-31 1985-08-31 Formulation

Publications (2)

Publication Number Publication Date
IT8648065A0 true IT8648065A0 (it) 1986-05-27
IT1191926B IT1191926B (it) 1988-03-31

Family

ID=26289290

Family Applications (1)

Application Number Title Priority Date Filing Date
IT48065/86A IT1191926B (it) 1985-05-28 1986-05-27 Formulazione farmaceutica liofilizzata di attivatore del plasminogeno dei tessuti e procedimento di preparazione relativo

Country Status (22)

Country Link
US (2) US4929444A (it)
JP (1) JPH0759517B2 (it)
AU (1) AU567236B2 (it)
BE (1) BE904830A (it)
CA (1) CA1300008C (it)
CH (1) CH665356A5 (it)
DE (1) DE3617752A1 (it)
DK (1) DK163173C (it)
ES (2) ES8800601A1 (it)
FI (1) FI85335C (it)
FR (1) FR2583984B1 (it)
GB (1) GB2176702B (it)
GR (1) GR861366B (it)
HU (1) HU195733B (it)
IL (1) IL78938A (it)
IT (1) IT1191926B (it)
LU (1) LU86444A1 (it)
NL (1) NL8601355A (it)
NO (1) NO171345C (it)
NZ (1) NZ216307A (it)
PT (1) PT82646B (it)
SE (1) SE462016B (it)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8601354A (nl) * 1985-05-28 1986-12-16 Wellcome Found Nieuwe samenstelling.
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
BE1001425A4 (fr) * 1986-05-12 1989-10-31 Wellcome Found Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association.
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
WO1992011866A1 (en) * 1991-01-14 1992-07-23 Duke University LAMININ SEQUENCE AS tPA ACTIVATOR
JP3559559B2 (ja) * 1992-06-03 2004-09-02 ジェネンテク，インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
ES2206602T3 (es) * 1995-10-23 2004-05-16 The Children's Medical Center Corporation Compuestos y metodos terapeuticos inhibidores de angiogenesis.
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
KR100477280B1 (ko) * 1995-12-13 2005-07-18 아보트 러보러터리즈 맥관형성에의한질환치료제
EP0827751B1 (en) * 1996-09-06 2003-02-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal composition containing tissue plasminogen activator and nicotinamide
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
US7670810B2 (en) * 2003-06-20 2010-03-02 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
AU2006236150A1 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (it) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
NL191755C (nl) * 1982-10-29 1996-07-02 Mitsui Toatsu Chemicals Plasminogeenactivator en trombolytisch middel.
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
NZ206699A (en) * 1982-12-30 1989-08-29 Bio Response Inc Process for the production of serum independent cell lines
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
GB8513358D0 (en) * 1985-05-28 1985-07-03 Wellcome Found Formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
ES8802439A1 (es) 1988-06-01
FI85335C (fi) 1992-04-10
GB8612780D0 (en) 1986-07-02
CA1300008C (en) 1992-05-05
NL8601355A (nl) 1986-12-16
DK163173B (da) 1992-02-03
BE904830A (fr) 1986-11-27
GB2176702A (en) 1987-01-07
NZ216307A (en) 1989-10-27
FI862227A0 (fi) 1986-05-27
SE8602405L (sv) 1986-11-29
HUT41638A (en) 1987-05-28
JPH0759517B2 (ja) 1995-06-28
IT1191926B (it) 1988-03-31
FR2583984A1 (fr) 1987-01-02
GB2176702B (en) 1989-07-05
NO171345B (no) 1992-11-23
ES555353A0 (es) 1987-11-16
NO862096L (no) 1986-12-01
IL78938A (en) 1993-02-21
PT82646B (pt) 1989-01-30
DE3617752A1 (de) 1986-12-04
DK246786D0 (da) 1986-05-27
US4929444A (en) 1990-05-29
HU195733B (en) 1988-07-28
ES8800601A1 (es) 1987-11-16
CH665356A5 (de) 1988-05-13
FI85335B (fi) 1991-12-31
LU86444A1 (fr) 1986-12-05
NO171345C (no) 1993-03-03
GR861366B (en) 1986-09-29
US4968617A (en) 1990-11-06
DE3617752C2 (it) 1988-06-30
FR2583984B1 (fr) 1989-06-02
DK246786A (da) 1986-11-29
SE462016B (sv) 1990-04-30
AU567236B2 (en) 1987-11-12
IL78938A0 (en) 1986-09-30
FI862227A (fi) 1986-11-29
SE8602405D0 (sv) 1986-05-27
PT82646A (en) 1986-06-01
AU5796486A (en) 1986-12-04
ES557374A0 (es) 1988-06-01
DK163173C (da) 1992-06-22
JPH06183995A (ja) 1994-07-05

Similar Documents

Publication Publication Date Title
IT8648065A0 (it) Formulazione farmaceutica liofilizzata di attivatore del plasminogeno dei tessuti e procedimento di preparazione relativo
NO171344C (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator
AU609390B2 (en) Cyclodextrinclathrates of carbacycline derivatives and their use as medicinal drugs
NO169493C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive peptid-derivater
GB2181346B (en) Pharmaceutical compositions and medical uses of dioxopiperidine derivatives
NO168988C (no) Anvendelse av en argininiumholdig buffer til formulering av stabile farmasoeytiske preparater inneholdende humanvevplasminogenaktivator
IT8847745A0 (it) Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
NO165398C (no) Analogifremgangsmaate og fremstilling av terapeutisk aktive nitrofuranderivater.
NO865204L (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzosyre- og benzosyreester-derivater.
IT8820073A0 (it) Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
IT8521938A0 (it) Sostanza anti-neoplastica, suoi preparati farmaceutici e relativo metodo di impiego
IT8868118A0 (it) Composizione e procedimento per il trattamento e la cura dei capelli
IT1183181B (it) Derivati del 3-metil-imidazo(4,5-c)pirazolo con attivita' terapeutica e procedimento per la loropreparazione
KR890701094A (ko) 활성성분의 피부조직 전이흡수를 보장하는 약제학적 제제형 및 그 조제방법
ES2023286B3 (es) Composicion cosmetica o farmaceutica de uso cutaneo y procedimiento para la preparacion de tal composicion
BG44709A3 (bg) Метод за получаване на 9-хлор-1,5-бензотиазепинови производни
NO171242C (no) Fremgangsmaate for fremstilling av hudpleiepreparater med keratolytisk og antiinflammatorisk virkning
IT8821634A0 (it) Composizioni farmaceutiche che favoriscono la cicatrizzazione di ferite e procedimento per prepararle
IT8767993A0 (it) Cosmetico dei capelli utilizzante composizione per indurre e stimola tale composizione re la crescita dei capelli e ridurre la caduta a base di derivati di alchilen diammino chinazolina associazione contenente tale composizione utilizzazione della composizione per la preparazione di un medicinale e procedimento di trattamento
DK173886D0 (da) 1-hydroxy-8-acyloxy-10-acyl-anthroner, deres fremstilling og deres anvendelse til human- eller veterinaermedicinske og kosmetiske formaal
NO172538C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 6-fenoksymetyl-4-hydroksytetrahydropyran-2-oner og 6-tiofen-oksymetyl-4-hydroksytetrahydropyran-2-oner
AU7945787A (en) Use of anipamil
NZ222084A (en) Peptides comprising epidermal growth factor domain fragments of clotting factor 1x and pharmaceutical compositions
IT8648619A0 (it) Preparati farmaceutici per il trattamento della vitiligine e della psoriasi
NO920192D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-substituerte-alfa-(heteroaryl)benzenetanaminer og anvendelse derav som medikamenter